Aprogen Biologics raises 2B KRW via rights issue
에이프로젠
007460
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2547
Risk-adjusted indicator based on 2547 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • New Shares Issued: 1,087,548 Shares
- • Issue Price per Share: 1,839 KRW
- • Total Funding: 2,000,000,772 KRW
- • Pre-issuance Shares Outstanding: 14,412,374 Shares
- • Dilution Rate: 7.55%
AI Analysis Summary
Aprogen Biologics, a subsidiary of Aprogen, Inc., announced a third-party allocation paid-in capital increase, issuing 1,087,548 common shares at 1,839 KRW per share, raising approximately 2.0 billion KRW. The funds are designated for operational expenses, specifically raw material purchases and factory operating costs in 2026. The issuance represents a 7.55% dilution to existing shareholders. The shares will be allocated to Aprogen, the largest shareholder, and will be subject to a one-year lock-up period. While the funding addresses operational needs, the dilution could negatively impact existing shareholder value.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.